Degrader-antibody conjugate (DAC)
An ADC that delivers a protein-destroying molecule instead of chemotherapy, hitting targets inside the cell that were previously unreachable.
Orum Therapeutics (ORM-5029, HER2-directed GSPT1 degrader; ORM-6151, CD33), Genentech (BRD4 degrader conjugates), and others. Solves the delivery and bioavailability problems of PROTACs and lets a non-cytotoxic mechanism be targeted to the tumour. Early clinical.
How it works
Antibody delivers a molecular glue or PROTAC payload; intracellular release triggers targeted degradation.
- Non-genotoxic payload
- Intracellular targets via antibody selectivity
- Potency per molecule lower than cytotoxics
- Early stage
Latest papers
topQuery for this technology: (TITLE:"degrader-antibody conjugate" OR ABSTRACT:"degrader-antibody conjugate" OR TITLE:"degrader antibody conjugate" OR ABSTRACT:"degrader antibody conjugate"). Results are unfiltered search hits about Degrader-antibody conjugate (DAC), not a curated reading list.